Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug

Journal of Clinical Pharmacology

Volumn 36, Issue 10, 1996, Pages 884-891

  Doose, D R ^a   Walker, S A ^a   Gisclon, L G ^a   Nayak, R K ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; EPILEPSY; FOCAL EPILEPSY; FOOD DRUG INTERACTION; HUMAN; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MALE; ORAL DRUG ADMINISTRATION; URINARY EXCRETION;

EID: 0029804193     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04754.x     Document Type: Article

References (24)

1. Maryanoff BE, Margul BL: Topiramate. Drugs of the Future 1989; 14:342-344.
2. Gardocki JF, Labinsky LS, Brown GL, Maryanoff BE: Anticonvulsant activity of McN-4853 (M) 2,3:4-bis-O-(L-methylethylidene)-β-D-fructopyranose sulfamate in mice and rats (abstract). Epilepsia 1986; 27:648-649.
3. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, et al: Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia, 1994; 35: 449-460.
4. Cooper JM, Stubbs RJ, Palmer ME: A capillary GC assay with NPD detection for the quantification of topiramate in human plasma (abstract). Presented at the Sixth Annual Meeting and Exposition of the American Association of Pharmaceutical Sciences, Washington, DC, November 17-21, 1991. Pharm Sci 1991;8(Suppl).
5. SAS Institute: SAS Users Guide: Statistics. Cary, NC: Statistical Analysis Systems, 1982.
6. Draper NR, Smith H: Applied Regression Analysis. Second edition. New York: John Wiley & Sons, 1981.
7. Welling PG: Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm 1977; 5:291-334.
8. Melander A: Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978; 3:337-351.
9. Kutt H: Overview of the pharmacokinetics of antiepileptic drugs. In, Faingold CL, Fromm GH (eds.): Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. Boca Raton, FL: CRC Press, 1992; 361-374.
10. Bialer M: Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993; 24:441-452.
11. Schecter PJ: Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27:19S-22S.
12. Vollmer K-O, von Hodenberg A, Kolle E-U: Pharmacokinetics and metabolism of gabapentin in rat, dog, and man. Arzneimittelforschung 1986; 36:830-839.
13. Foot M, Wallace J: Gabapentin. Epilepsy Res Suppl 1991; 3: 109-114.
14. Perucca E, Pisanni F: Pharmacokinetics and interactions of the new antiepileptic drugs. Epilepsy Res Suppl 1991; 3:79-88.
15. Thomas AH, Brodie MJ: Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 1992; 23:216-230.
16. Haegle KD, Schecter PJ: Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986; 40:581-585.
17. Scheyer RD, Cramer JA: Pharmacokinetics of antiepileptic drugs. Semin Neurol 1990; 4:414-421.
18. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL: How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261:3273-3277.
19. Leppik IE, Graves NM: Felbamate. In, Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penny JK, (eds.): Antiepileptic Drugs. Second edition. New York: Raven Press, 1989; 938-990.
20. Cohen AF, Land GS, Breimer DD, Yuen WC, Wanton C, Peck AW: Lamotigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42:535-541.
21. Jawad S, Yuen WC, Peck AW, Oxley JR, Richens A: Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987; 1:194-201.
22. Ramsay RE, Pellock JM, Garnett WR, Sanchez RE, Valakas AM, Wargin WA, et al: Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991; 10:191- 200.
23. Wilensky AJ, Fuel PN, Ojemann LM, Kupferberg HJ, Levy RH: Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia 1985; 26:602-606.
24. Frisk-Holmberg M, Kerth P, Meyer PH: Effect of food on the absorption of vigabatrin. Br J Clin Pharmacol 1989; 27:23S-25S.